Clinical Trial Sponsors: National Institutes of Health Clinical Center (CC)

  Source:		NCT02338986

    		Collection of Plasma From People Who
     		Recovered From or Were Vaccinated to
			Emerging Infectious Diseases

			Enrolling by invitation

			First Update January 14, 2015
			Last Update July 23, 2019

			Brief Summary
			Background: - There are more emerging
			infectious diseases recently. Some could affect
			many people. Some like Severe Acute Respiratory Syndrome
			(SARS) or Middle East Respiratory Syndrome
			(MERS) are caused by new germs. Sometimes
			known germs suddenly infect new and large
			areas, like Ebola. Many of these diseases don
			t have good treatments available. Researchers
			may be able to develop a treatment by using
			antibodies against these infections. Objective:
			- To collect antibodies from people with
			high levels of antibodies to the diseases being
			studied. Eligibility: - Ages 18-70 years old who
			weigh at least 110 pounds. They may have
			been infected with or vaccinated for one of
			the new infections researchers are studying.
			Design: - Participants will be screened with
			medical history and blood tests. Researchers
			will determine if the participant can have
			apheresis. - Participants will have apheresis.
			First, they will be interviewed. Then, a needle
			will be placed in a vein. Blood will be drawn,
			and a machine will separate the blood cells
			from the antibodies and protein. The blood
			cells will then be returned to the participant
			through another vein. It takes about 60 minutes
			for the actual collection. - Participants will be
			asked to have the procedure at least 3 times.
			They can participate in up to 20 sessions total
			as part of this study. There must be at least
			7 days between sessions.

			Detailed Description
			The administration of convalescent plasma is
			often used for treatment of emerging infectious
			diseases. This natural history protocol will
			collect plasma from subjects that were
			vaccinated to or recovered from an emerging
			infectious disease of interest, in a manner that
			the plasma can be given to other subjects as
			a therapeutic. Any administration of plasma
			to subjects will be under a separate protocol.

			15214887 Retrospective comparison of
			convalescent plasma with continuing high-dose
			methylprednisolone treatment in SARS patients.

			9988160 Treatment of Ebola hemorrhagic
			fever with blood transfusions from convalescent
			patients. International Scientific and Technical

			21248066 Convalescent plasma treatment
			reduced mortality in patients with severe
			pandemic influenza A (H1N1) 2009 virus

     		                         Embed       Tweet       Print